Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Florian Lipsmeier

Christian Klein

Pablo Umana

Guy Georges

Joerg Moelleken

Stefan Klostermann

Apollon Papadimitriou

Barbara Weiser

Christian Gossens

Michael Lindemann

Felix Bormann

Detlef Wolf

Daniela Matscheko

Jasmin Sydow-andersen

Sebastian Fenn

Alexander Haas

Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the axial motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.

Digital biomarker

Growing community of inventors

Basel, Switzerland

Florian Lipsmeier